Glomerular Immunotherapy: Target Disease, Prevent Harm

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Immunotherapy needs a disease-specific rationale, a measurable response plan, and prevention of predictable treatment harms.

Glomerular Immunotherapy: Target Disease, Prevent Harm: six-panel learning summary. Full text follows below.
Download infographic (PNG) · Download Markdown · Read text version ·

Text version

Treatment follows the mechanism

Glucocorticoids, B-cell therapy, cytotoxic agents, antimetabolites, calcineurin inhibitors, and complement-directed approaches affect different immune pathways. Selection depends on diagnosis, activity, prior treatment, kidney function, and the evidence for that disease.

Recognize treatment vulnerability

Infection, cytopenias, diabetes, hypertension, bone disease, fertility concerns, pregnancy potential, and medication interactions shape risk. Severe active disease can justify intensive therapy, but the prevention plan must begin before complications emerge.

Establish a baseline

Review infection screening, vaccination status, blood counts, chemistry, liver tests, medication interactions, and reproductive plans as appropriate to the regimen. Coordinate prophylaxis and monitoring with the specific agents and cumulative immunosuppressive burden.

Plan induction and maintenance

State the therapeutic objective, expected response markers, taper or transition strategy, and reassessment schedule. Distinguish persistent active disease from residual scarring or medication toxicity before intensifying immunosuppression.

Monitor efficacy and burden

Follow proteinuria, kidney function, disease activity, infection, blood counts, and agent-specific adverse effects. Support bone health, discuss fertility preservation when relevant, and make the patient’s warning-sign and contact plan explicit.

Evidence update: ADVOCATE

The historical ADVOCATE avacopan trial was retracted in 2026. Its reported benefit is not reliable supporting evidence. Cite the trial as retracted with the retraction notice, and assess other evidence separately using current specialist guidance.

Self-check: Name the response measure, infection-prevention plan, and toxicity monitoring that should accompany a disease-specific immunosuppressive regimen.

Continue learning

This graphic summarizes a topic. The full educational pages provide the broader discussion and references.